Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any ot

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any ot

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 54.4 mg/ml (equivalent: flucloxacillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: erythrosine; sodium citrate; sodium benzoate; sucrose; ammonium glycyrrhizinate; disodium edetate; saccharin sodium; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 27.2 mg/ml equivalent to flucloxacillin 25 mg/ml;  ; flucloxacillin sodium monohydrate 28.63 mg/ml equivalent to flucloxacillin 25 mg/ml - powder for syrup - 125 mg/5ml - active: flucloxacillin sodium monohydrate 27.2 mg/ml equivalent to flucloxacillin 25 mg/ml   excipient: ammonium glycyrrhizinate disodium edetate dihydrate erythrosine menthol flavour 17410157 pineapple flavour 17410011 saccharin sodium sodium benzoate sodium citrate dihydrate sucrose active: flucloxacillin sodium monohydrate 28.63 mg/ml equivalent to flucloxacillin 25 mg/ml excipient: citric acid monohydrate colloidal silicon dioxide disodium edetate dihydrate lemon flavour 17.41.0212 menthol flavour 17410157 saccharin sodium sodium benzoate sodium citrate sorbitol strawberry flavour 17.43.2172 xanthan gum - the treatment of infections due to gram-positive organisms, including infections caused by ?-lactamase producing staphylococci

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 54.4 mg/ml equivalent to flucloxacillin 50 mg/ml;  ; flucloxacillin sodium monohydrate 57.26 mg/ml equivalent to flucloxacillin 50 mg/ml - powder for syrup - 250 mg/5ml - active: flucloxacillin sodium monohydrate 54.4 mg/ml equivalent to flucloxacillin 50 mg/ml   excipient: ammonium glycyrrhizinate disodium edetate dihydrate erythrosine menthol flavour 17410157 pineapple flavour 17410011 saccharin sodium sodium benzoate sodium citrate dihydrate sucrose active: flucloxacillin sodium monohydrate 57.26 mg/ml equivalent to flucloxacillin 50 mg/ml excipient: citric acid monohydrate colloidal silicon dioxide disodium edetate dihydrate lemon flavour 17.41.0212 menthol flavour 17410157 saccharin sodium sodium benzoate sodium citrate sorbitol strawberry flavour 17.43.2172 xanthan gum - the treatment of infections due to gram-positive organisms, including infections caused by ?-lactamase producing staphylococci

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 27.2 mg/ml (equivalent: flucloxacillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: ammonium glycyrrhizinate; sodium benzoate; sucrose; saccharin sodium; disodium edetate; sodium citrate; erythrosine; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - flucloxacillin sodium monohydrate, quantity: 281.89 mg - capsule - excipient ingredients: methyl hydroxybenzoate; titanium dioxide; indigo carmine; gelatin; magnesium stearate; propyl hydroxybenzoate; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - flucloxacillin sodium monohydrate, quantity: 563.78 mg - capsule - excipient ingredients: indigo carmine; methyl hydroxybenzoate; propyl hydroxybenzoate; gelatin; magnesium stearate; titanium dioxide; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

United States - English - NLM (National Library of Medicine)

avkare, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal i

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic